# A Study to Evaluate Efalizumab Compared With Cyclosporine As an Immunosuppressant Regimen in De Novo Renal Transplantation

> **NCT00729768** · PHASE2,PHASE3 · WITHDRAWN · sponsor: **Genentech, Inc.**

## Conditions studied

- Kidney Transplantation

## Interventions

- **DRUG:** basiliximab
- **DRUG:** efalizumab
- **DRUG:** mycophenolate mofetil
- **DRUG:** corticosteroids
- **DRUG:** cyclosporine

## Key facts

- **NCT ID:** NCT00729768
- **Lead sponsor:** Genentech, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2017-06-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00729768

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00729768, "A Study to Evaluate Efalizumab Compared With Cyclosporine As an Immunosuppressant Regimen in De Novo Renal Transplantation". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00729768. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*